Biometheus: Placebo parity

Biometheus LLC has a biomarker for a polymorphism that can prospectively identify patients who will respond to placebo in clinical trials. The marker could allow companies to exclude these patients up front and cut trial sizes in half.

Last week, Biometheus emerged from stealth mode and announced an exclusive option to IP from Beth Israel Deaconess Medical Center that covers a marker for a polymorphism in the catechol-O-methyl-transferase (COMT) gene...